[The introduction of 9,9-dioxopromethazine (Prothanon) into the treatment of skin diseases in hospitalized patients].
D001769:Blood / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003874:Dermatitis Herpetiformis / Q000188:drug therapy; D003879:Dermatologic Agents; D004342:Drug Hypersensitivity / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D004586:Electrophoresis; D005221:Fatigue / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D010919:Placebos; D011398:Promethazine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D014556:Urine / Q000187:drug effects; D014581:Urticaria / Q000188:drug therapy
D001786:Blood Glucose; D003879:Dermatologic Agents; D006634:Histamine H1 Antagonists; D010919:Placebos; D011398:Promethazine
Der Einsatz von 9.9-Dioxopromethazin (Prothanon) bei stationär behandelten Hautkrankheiten.